L@B Brief - May 2026
COMMENT: AstraZeneca's welcome return to the UK
THE ANNOUNCEMENT that AstraZeneca is resuming £300 million of previously frozen UK investment is welcome news for the UK life sciences sector. But for laboratory equipment and technology suppliers, the most interesting aspect is not just that the investment is happening, but what kind of laboratory it is creating, and what that signals about how pharmaceutical R&D procurement is evolving.
AstraZeneca has been building towards the lab of the future model for some time, but had paused its Cambridge investment amid frustration over NHS drug pricing negotiations, and scrapped a separate £450 million investment in its Merseyside vaccine manufacturing facility. Now scientists are being recruited to support ‘a growing fleet of automated and semi-automated experimental equipment,’ enabling automated experimental platforms ‘designed to ensure smooth, efficient data generation and data flows across a digital lab ecosystem’. Senior roles focus on ‘the orchestration of complex lab processes’ and ensuring data flows seamlessly across systems.
This describes a laboratory model fundamentally different from the traditional instrument-and-analyst setup. The emphasis is on integrated platforms, orchestrated workflows, seamless data transfer between systems, and minimal manual intervention.
This is not an AstraZeneca idiosyncrasy - it is an industry shift
Thermo Fisher Scientific's general manager of laboratory automation recently stated that ‘there has been, in almost every large pharma company, strategic investments towards the automated digital lab’.
A 2024 Capgemini Research Institute report based on 702 respondents from 235 pharmaceutical and biopharma labs found that 92% of pharma organisations cited the need to accelerate drug development cycle times as a top driver for next-generation lab investment. Large pharma organisations were projected to almost double their investment in lab transformation to nearly 7% of revenue by 2025, up from 4%. GSK is on a parallel course, with its R&D technology division actively leading multiple ‘Lab of the Future’ initiatives and strategies to digitalise lab data capture from point of generation.
The new model does not deprioritise instrumentation - if anything it requires more of them - but it has the potential to change what customers are buying. Standalone instruments with proprietary data formats and manual operating procedures may be a poor fit. What is valued is connectivity: instruments that integrate into automated workflows, generate structured and accessible data, and can be managed as part of a broader digital ecosystem.
AstraZeneca's return to UK investment is good news and the terms on which it has returned tell us something important about the direction pharmaceutical laboratory procurement is heading.
If you want to sell to labs being developed or refurbished, have a look at the new free membership benefit included with this newsletter. Our Tender Alert Service manager, Natalia Pan, has produced an excel sheet containing details of 20 current projects listing the spend and the client on each. I’m sure you will find it useful!
Toodle Pip!
Jacqueline
INSIDE this ISSUE
FREE with this issue - Excel sheet detailing lab construction and refurbishment projects in the UK and Ireland.
Opportunities in California, Illinois, Germany and Poland...This issue also includes a separate Excel sheet detailing lab construction and refurbishment projects in the UK and Ireland.
Member news: Faster antibody analysis from GAMBICA newest member NOVILYTIC
Also inside...
GAMBICA events and Industry events including new opportunities for marketing and after-sales professionals